tetano
Editor, Senior Moderator
Vasc Med
. 2023 Jun 1;1358863X231159945.
doi: 10.1177/1358863X231159945. Online ahead of print. Outcomes in patients discharged with extended venous thromboembolism prophylaxis after hospitalization with COVID-19
Love Patel[SUP] 1 [/SUP], Ashley Stenzel[SUP] 2 [/SUP], Christopher Van Hove[SUP] 3 [/SUP], Abbey Sidebottom[SUP] 2 [/SUP], Rajesh Kethireddy[SUP] 1 [/SUP], Ngoc Ha[SUP] 2 [/SUP], David Beddow[SUP] 4 [/SUP], Jesse Manunga[SUP] 5 [/SUP], Ghaziuddin Qadri[SUP] 1 [/SUP], Justin Kirven[SUP] 1 [/SUP], Nedaa Skeik[SUP] 6 [/SUP]
Affiliations
Background: Venous thromboembolism (VTE) is a known complication of coronavirus disease (COVID-19) in patients requiring hospitalization and intensive care. We examined the association between extended pharmacological VTE prophylaxis and outcomes among patients hospitalized with COVID-19.
Methods: This was a retrospective cohort study of patients with an index positive SARS-CoV-2 polymerase chain reaction (PCR) test at the time of, or during hospitalization. Patients who were prescribed extended pharmacological VTE prophylaxis were compared against patients who were not. Multivariable logistic regression was used to produce odds ratio (OR) estimates and Cox proportional hazard models for hazard ratios (HR) with 95% CI to examine the association between pharmacological VTE prophylaxis and outcomes of interest. Primary outcomes were 30- and 90-day VTE events. Secondary outcomes included 30- and 90-day mortality, 30-day superficial venous thrombosis (SVT), acute myocardial infarction (MI), acute ischemic stroke, critical limb ischemia, clinically significant bleeding, and inpatient readmissions.
Results: A total of 1936 patients were included in the study. Among them, 731 (38%) were discharged on extended pharmacological VTE prophylaxis. No significant difference was found in 30- and 90-day VTE events among groups. Patients discharged on extended VTE prophylaxis showed improved survival at 30 (HR: 0.35; 95% CI: 0.21-0.59) and 90 days (HR: 0.36; 95% CI: 0.23-0.55) and reduced inpatient readmission at 30 days (OR: 0.12; 95% CI: 0.04-0.33) when compared to those without.
Conclusion: Patients discharged on extended VTE prophylaxis after hospitalization due to COVID-19 had similar thrombotic events on follow-up. However, use of extended VTE prophylaxis was associated with improved 30- and 90-day survival and reduced risk of 30-day inpatient readmission.
Keywords: COVID-19; anticoagulation; hospital discharge; prophylaxis; venous thromboembolism (VTE).
. 2023 Jun 1;1358863X231159945.
doi: 10.1177/1358863X231159945. Online ahead of print. Outcomes in patients discharged with extended venous thromboembolism prophylaxis after hospitalization with COVID-19
Love Patel[SUP] 1 [/SUP], Ashley Stenzel[SUP] 2 [/SUP], Christopher Van Hove[SUP] 3 [/SUP], Abbey Sidebottom[SUP] 2 [/SUP], Rajesh Kethireddy[SUP] 1 [/SUP], Ngoc Ha[SUP] 2 [/SUP], David Beddow[SUP] 4 [/SUP], Jesse Manunga[SUP] 5 [/SUP], Ghaziuddin Qadri[SUP] 1 [/SUP], Justin Kirven[SUP] 1 [/SUP], Nedaa Skeik[SUP] 6 [/SUP]
Affiliations
- PMID: 37259526
- DOI: 10.1177/1358863X231159945
Background: Venous thromboembolism (VTE) is a known complication of coronavirus disease (COVID-19) in patients requiring hospitalization and intensive care. We examined the association between extended pharmacological VTE prophylaxis and outcomes among patients hospitalized with COVID-19.
Methods: This was a retrospective cohort study of patients with an index positive SARS-CoV-2 polymerase chain reaction (PCR) test at the time of, or during hospitalization. Patients who were prescribed extended pharmacological VTE prophylaxis were compared against patients who were not. Multivariable logistic regression was used to produce odds ratio (OR) estimates and Cox proportional hazard models for hazard ratios (HR) with 95% CI to examine the association between pharmacological VTE prophylaxis and outcomes of interest. Primary outcomes were 30- and 90-day VTE events. Secondary outcomes included 30- and 90-day mortality, 30-day superficial venous thrombosis (SVT), acute myocardial infarction (MI), acute ischemic stroke, critical limb ischemia, clinically significant bleeding, and inpatient readmissions.
Results: A total of 1936 patients were included in the study. Among them, 731 (38%) were discharged on extended pharmacological VTE prophylaxis. No significant difference was found in 30- and 90-day VTE events among groups. Patients discharged on extended VTE prophylaxis showed improved survival at 30 (HR: 0.35; 95% CI: 0.21-0.59) and 90 days (HR: 0.36; 95% CI: 0.23-0.55) and reduced inpatient readmission at 30 days (OR: 0.12; 95% CI: 0.04-0.33) when compared to those without.
Conclusion: Patients discharged on extended VTE prophylaxis after hospitalization due to COVID-19 had similar thrombotic events on follow-up. However, use of extended VTE prophylaxis was associated with improved 30- and 90-day survival and reduced risk of 30-day inpatient readmission.
Keywords: COVID-19; anticoagulation; hospital discharge; prophylaxis; venous thromboembolism (VTE).